Business Overview: Compass Therapeutics, Inc. (Nasdaq: CMPX)

---

Executive Summary

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company built around a proprietary bispecific antibody discovery platform (StitchMabs) that targets the intersection of tumor angiogenesis and immune evasion. The company's pipeline is anchored by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody licensed from ABL Bio, which has advanced furthest through a Phase 2/3 registrational study (COMPANION-002) in second-line biliary tract cancer (BTC), a rare and historically underserved gastrointestinal malignancy. Behind tovecimig sit three earlier-stage immuno-oncology candidates — CTX-471 (a CD137 agonist), CTX-8371 (a PD-1 x PD-L1 bispecific), and CTX-10726 (a PD-1 x VEGF-A bispecific) — each designed to combine checkpoint blockade with a complementary mechanism in an attempt to improve on single-agent immunotherapy response rates.

The company generates no product revenue and, like most clinical-stage biopharmaceutical companies, funds its entire operation through the capital markets, relying on equity issuance and existing cash reserves to advance its trials. Its investment case therefore rests almost entirely on binary clinical and regulatory catalysts rather than on any recurring commercial engine, and its ultimate value will be determined by whether tovecimig and the immuno-oncology pipeline can generate data compelling enough to support regulatory approval and, eventually, third-party licensing or M&A interest from larger oncology franchises.

The single most decision-relevant fact for investors today is the collision between Compass's regulatory strategy and FDA feedback on tovecimig: on September 22, 2026, the company disclosed that the FDA has recommended a new clinical trial demonstrating a survival benefit before Compass submits a Biologics License Application (BLA) for tovecimig in previously treated BTC — a path the company disputes given COMPANION-002's statistically significant response-rate and progression-free survival benefit. This directly threatens the near-term BLA timeline previously guided for later in 2026, even though the balance sheet ($180 million in cash and marketable securities as of June 30, 2026, guided to fund operations into 2028) gives Compass room to negotiate with the agency or initiate a confirmatory trial without an immediate financing crisis.

---

1. Core Business Model & How They Work

Compass operates the standard clinical-stage biopharmaceutical model: it does not manufacture, market, or sell any product, and instead invests essentially all of its capital into the discovery, in-licensing, and clinical development of antibody therapeutics for oncology indications with significant unmet need. Its differentiation is technical rather than commercial — the in-house StitchMabs platform is designed to generate bispecific antibodies through unbiased screening rather than rational engineering of two known binders, which the company argues produces molecules with more favorable biophysical and pharmacologic properties. Compass supplements internally discovered candidates with in-licensed assets (tovecimig from ABL Bio; CTX-471 originating from an Adimab collaboration), giving it a four-program pipeline spanning both anti-angiogenic/checkpoint bispecifics and pure immune-agonist mechanisms. All clinical drug supply is manufactured by third-party contract manufacturers, and any future revenue — to the extent it materializes — would come from milestone payments, licensing deals, or, if approved, product sales, none of which are yet material.

Key Operational Drivers

1. Tovecimig clinical and regulatory execution in biliary tract cancer — the near-term catalyst that determines whether Compass has a path to its first approved product and first source of commercial revenue.
2. Capital allocation across a four-program pipeline — management must balance funding a potential BLA-enabling confirmatory trial for tovecimig against continued investment in the earlier-stage CTX-471, CTX-8371, and CTX-10726 immuno-oncology assets.
3. Licensing and milestone obligations to ABL Bio and Adimab — structured as milestone-plus-royalty deals, these agreements dilute long-run economics on any approved product but lowered upfront cash costs during discovery.
4. Balance sheet discipline — with no product revenue, cash runway (guided into 2028) is the ultimate constraint on how many shots on goal the pipeline gets before additional dilutive financing is required.
5. Talent and platform leverage — a lean, 39-employee organization (as of year-end 2025) that depends heavily on external contract research organizations and manufacturers to execute trials and supply.

---

3. Product Portfolio

---

4. Competitive Landscape

Compass competes on two very different fronts. In biliary tract cancer, tovecimig would need to differentiate against an evolving standard of care that already includes first-line chemo-immunotherapy combinations (gemcitabine/cisplatin plus a PD-L1 inhibitor) and genomically targeted second-line options such as FGFR2 and IDH1 inhibitors, all developed and marketed by companies with far greater commercial infrastructure. In the broader immuno-oncology bispecific space, Compass is a small player racing well-capitalized incumbents and other clinical-stage biotechs also pursuing PD-1/PD-(L)1-based bispecifics and next-generation checkpoint/costimulatory combinations. Compass's advantage in either arena is narrow: a differentiated mechanism and early efficacy signals, not scale, manufacturing cost, or commercial reach.

Key Competitors:

• Large-cap oncology franchises (Merck, Bristol-Myers Squibb, Roche/Genentech, AstraZeneca) that already market approved checkpoint inhibitors and anti-angiogenic agents used as backbone therapy across the same tumor types Compass is targeting.
• Targeted-therapy incumbents in biliary tract cancer (developers of FGFR2 and IDH1 inhibitors) that address the same genomically-defined second-line BTC population tovecimig is pursuing.
• Other bispecific and multispecific antibody developers (including large pharma internal programs and clinical-stage peers pursuing PD-1 x VEGF and CD137-directed mechanisms) racing toward differentiated combination-immunotherapy data in overlapping indications.
• Emerging modalities such as antibody-drug conjugates and cell therapies, which offer alternative mechanisms for the same relapsed/refractory patient populations.

Compass's small scale means it will likely need to partner, be acquired, or heavily out-license any approved asset to compete commercially against these incumbents.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• A proprietary bispecific discovery platform (StitchMabs) supported by a growing patent estate (nearly 100 issued patents and applications across its three lead programs).
• A lead asset (tovecimig) with statistically significant, clinically meaningful Phase 2/3 response-rate and progression-free survival data in a rare tumor type with no dominant standard of care in the second line.
• A pipeline built around a differentiated scientific thesis — combining anti-angiogenic and immune-checkpoint mechanisms in single bispecific molecules — rather than dependence on one target or mechanism.
• A cash position ($180 million as of mid-2026, guided into 2028) that is unusually long-dated for a company of its size, reducing near-term financing risk relative to peers.

Strategic Risks & Vulnerabilities

1. Regulatory risk on the lead asset: The FDA's September 2026 recommendation that Compass run an additional survival-focused trial before filing a BLA for tovecimig directly threatens the timeline and value of the company's most advanced program.
2. Clinical risk across an early pipeline: CTX-471, CTX-8371, and CTX-10726 are all pre-Phase 2 or earlier, and none has generated data sufficient to de-risk its path to approval; any of the four programs could fail in later-stage trials.
3. Financing and dilution risk: Despite the 2028 runway guidance, a confirmatory trial for tovecimig or expanded Phase 2 programs across the immuno-oncology pipeline would likely require additional equity financing, which is dilutive to existing shareholders — particularly if raised from a position of regulatory weakness.
4. Licensing/economic risk: Milestone and royalty obligations to ABL Bio and Adimab reduce the economics Compass would retain on any approved product, and the company holds ex-South Korea rights to tovecimig only.

---

6. Financial Overview

---

7. Summary Conclusion

Compass Therapeutics is a small, single-asset-driven clinical-stage biopharmaceutical company whose near-term valuation hinges heavily on the regulatory fate of tovecimig in biliary tract cancer. The underlying science — a proprietary bispecific platform, statistically significant Phase 2/3 efficacy data, and a diversified early pipeline of immune-agonist and checkpoint bispecifics — gives the company more optionality than many peers of its size, and a well-funded balance sheet (cash guided into 2028) buys time that many clinical-stage biotechs do not have. But the September 2026 FDA feedback recommending an additional survival trial before a BLA submission is a material setback to the timeline the market had been pricing in, and it crystallizes the core risk of the business model: without an approved product, Compass remains entirely dependent on regulatory judgment calls and continued access to capital markets. Investors should watch closely how the company's ongoing FDA dialogue resolves, since it will determine whether tovecimig's next catalyst is a BLA filing or a multi-year confirmatory trial.